Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.47 |
| ▸ | NRAS | P01111 | 6/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15193536 | 0.88 | FLT3 (0.53) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL15193533 | 0.88 | FLT3 (0.53) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL15194071 | 0.85 | IRAK4 (0.49) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL15194066 | 0.85 | IRAK4 (0.49) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL15193072 | 0.84 | FLT3 (0.47) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL2036766 | 0.84 | JAK2 (0.42) | IRAK4JAK2JAK1JAK3FYN | |
| SCHEMBL2052909 | 0.81 | FLT3 (0.46) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL2052907 | 0.81 | FLT3 (0.46) | FLT3NRASIRAK4IRAK1LCK | |
| SCHEMBL2033609 | 0.81 | FLT3 (0.43) | FLT3JAK2JAK1JAK3 | |
| SCHEMBL2033606 | 0.81 | FLT3 (0.43) | FLT3JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FLT3 21/4885NRAS 486/4885IRAK4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.